Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
The system is powered by BrainSense technology, which has received approval from USFDA
The hospital said the new centre will improve access to specialised interventions such as Deep Brain Stimulation
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Subscribe To Our Newsletter & Stay Updated
